期刊文献+

N端前体脑钠肽和胱抑素C对心肾综合征的诊断价值 被引量:5

Diagnostic value of N-terminal pro-brain natriuretie peptide and cystatin C in cardiorenal syndrome
在线阅读 下载PDF
导出
摘要 目的观察N端前体脑钠肽(NT-proBNP)和胱抑素C(CysC)在心肾综合征中的诊断价值。方法选择2010年1月至2012年6月在我院就诊的心力衰竭患者291例,按照是否具有肾功能衰竭,分为心肾综合征组(126例)和单纯心力衰竭组(165例)。其中心肾综合征按照心功能分级分为:Ⅱ级53例,Ⅲ级62例,Ⅳ级11例,按照肾功能不全的严重程度分为肾功能储备代偿(Ⅰ组)27例,肾功能不全失代偿(Ⅱ组)32例,肾功能衰竭(Ⅲ组)29例,尿毒症(Ⅳ组)38例。并观察NT-proBNP,CysC,血肌酐(SCr)和左心室射血分数(LVEF)的变化。结果心肾综合征组的NT-proBNP,CysC和SCr水平较单纯心力衰竭组明显提高(P<0.01),而LVEF水平较单纯心力衰竭组明显降低(P<0.01)。心肾综合征患者血清NT-proBNP,CysC和SCr水平随着心力衰竭分级和肾功能分期升高而升高(P<0.01),心力衰竭分级Ⅱ级、Ⅲ级和Ⅳ级的NT-proBNP(1.97±0.63)μg/Lvs(2.73±0.76)μg/Lvs(3.33±1.09)μg/L、CysC(1.47±0.43)mg/Lvs(1.84±0.61)mg/Lvs(2.25±0.54)mg/L、SCr(276.43±55.86)μmol/Lvs(462.98±72.43)μmol/Lvs(555.07±102.92)μmol/L(均P<0.01);肾功能分期Ⅰ组、Ⅱ组、Ⅲ组和Ⅳ组的NT-proBNP(1.44±0.28)μg/Lvs(2.29±0.87)μg/Lvs(2.78±1.09)μg/Lvs(3.09±0.98)μg/L、CysC(0.97±0.12)mg/Lvs(1.18±0.21)mg/Lvs(1.65±0.65)mg/Lvs(2.76±0.87)mg/L、SCr(167.91±37.32)μmol/Lvs(226.27±58.59)μmol/Lvs(448.58±67.48)μmol/Lvs(649.43±117.16)μmol/L(均P<0.01),而LVEF值随着心力衰竭分级Ⅱ级(48.32±10.34)%vsⅢ级(42.65±11.56)%vsⅣ级(31.37±9.64)%和肾功能分期Ⅰ组(55.76±10.87)%vsⅡ组(46.87±11.76)%vsⅢ组(39.87±12.87)%vsⅣ组(36.54±10.75)%升高而降低(P<0.01)。结论联合NT-proBNP和CysC的检测对心肾综合征的诊断具有重要意义,可以作为心肾综合征疾病严重程度的指标。 Objective To observe the significance of N-terminal pro-brain natriuretic peptide(NT-proBNP) and cystatin C(Cys C) in patients with cardiorenal syndrome. Methods A total of 291 patients with heart failure in the hospital,from January 2010 to June 2012 ,in accordance with renal failure,were divided into cardiorenal syndrome group ( n =126) and simple heart failure group (165 cases). According to cardiac function classification, the patients with cardiorenal syndrome were divided into grade II (53 cases) ,grade III (62 cases) and grade IV(11 cases). In accordance with the severity of renal insufficiency, the patients with cardiorenal syndrome were divided into renal reserve compensatory ( I group,27 cases) ,kidney dysfunction decompensation ( II group, 32 cases), renal failure ( III group, 29 cases),uremia (IV group,38 cases). The levels of NT-proBNP,Cys C,serum creatinine(SCr) and left ventricular ejection fraction(LVEF) were observed in the patients. Results Compared with simple heart failure group,the levels of NT-proBNP,Cys C and SCr in cardiorenal syndrome group improved significantly (P 〈 0.01), while the levels of LVEF in cardiorenal syndrome group were significantly lower than those in simple heart failure group( P 〈0.01). In cardiorenal syndrome group, the levels of NT-proBNP, Cys C and SCr increased as the heart failure stage and renal insufficiency period increased( P 〈0.01), in cardiac function classification grade II , III and IV, NT-proBNP ( 1.97 ± 0.63) μg/L vs (2.73±0.76) μg/L vs (3.33±1.09) μg/L,Cys C(1.47±0.43) mg/L vs (1.84±0.61) mg/L vs (2. 25±0.54) mg/L,SCr(276.43±55.86) μmol/L vs (462.98±72.43) μmol/L vs (555.07±102.92)μmol/L(all P 〈 0.01) lrenal stage group I ,group II ,group II ,group IV NT- proBNP: (1.44±0.28) μg/L vs (2.29±0.87) μg/L vs (2.78±1.09) μg/L vs (3.09±0.98) μg/L,Cys C(0.97±0.12) mg/L vs (1. 184±0.21) mg/L vs (1.65±0.65) mg/L vs (2.76±0.87) mg/L,SCr (167.91±37.32) μmol/L vs (226.27±58.59)μmol/L vs (448.58±67.48) μmol/L vs (649.43±117.16) μmol/L (all P 〈0.01), while the levels of LVEF decreased inversely as the heart failure stage, grade II (48. 32±10. 34) }/0 vs grade II (42.65±11.56)% vsgrade III(31.37±9.64)% and renal insufficiency period increased, group I (55.76±10.87)% vs group II (46.87±11.76)% vs group III (39.87±12.87)% vs group IV (36.54±10.75) % ( P 〈0.01). Conclusion Detection of NT-proBNP combined with Cys C has very important value in cardiorenal syndrome as indicators of the severity as cardiorenal syndrome.
出处 《临床荟萃》 CAS 2013年第4期409-411,415,共4页 Clinical Focus
关键词 心力衰竭 充血性 肾功能不全 利钠肽 heart failure, congestive renal insufficiency natriuretic peptide, brain
  • 相关文献

参考文献13

  • 1Ben Shoshan J, Entin-Meer M, Guzner-Gur H, et al. The cardiorenai syndrome: a mutual approach to concomitant cardiac and renal failure[J]. Isr Med Assoe J,2012,14(9) :570- 576.
  • 2Santoro A. Heart failure and cardiorenal syndrome in the elderly[J]. J Nephrol,2012,25 (Suppl 19):S67-S72.
  • 3Eren Z,Ozveren O, Buvukoner E, et al. A single-centre study of acute cardiorenal syndrome: incidence, risk factors and consequences[J]. Cardiorenal Med, 2012,2(3) : 168-176.
  • 4Whaley-Connell A, Sowers JR. Oxidative stress in the cardiorenal metabolic syndrome [J]. Curr Hypertens Rep, 2012,14(4) :360-365.
  • 5Sowers JR, Whaley-Connell A, Hayden MR. The role of overweight and obesity in the cardiorenal syndrome [J]. Cardiorenal Med,2011,1(1) :5-12.
  • 6Chan EJ, Dellsperger KC. Cardiorenal syndrome: the clinical cardiologists' perspective[J]. Cardiorenal Med, 2011,1 ( 1 ) : 13- 22.
  • 7Palazzuoli A, Geyer A, Malandrino A, et al. Current therapeutic strategies in eardiorenal syndrome[J]. Minerva Cardioangiol, 2012,60(4) :375-383.
  • 8Du JB, Da C H, Zhao Y, et al. The role o{ brain natriuretic peptide and serum triiodothyronine in the diagnosis and prognosis of chronic heart failure[J] Aeta Cardiol, 2012, 67 (3) :291-296.
  • 9Coats CJ, Parisi V, Ramos M, et a[, Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease [J]. Am J Cardiol,2013,111(1) :111-117.
  • 10Carlsen CM,Bay M,Kirk V,et al. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N- terminal pro brain natriuretic peptide: a 10 year analysis from the Copenhagen Hospital Heart Failure Study[J]. Eur J Heart Fail,2012,14(3) :240-247.

同被引文献80

  • 1Baraldi E,Filippone M. Chronic lung disease after premature birth[J].{H}New England Journal of Medicine,2007,(19):1946-1955.
  • 2Abman S H. Bronchopulmonary dysplasia:"a vascular hypothesis"[J].{H}American Journal of Respiratory and Critical Care Medicine,2001,(10 Pt 1):1755-1756.
  • 3Stoll B J,Hansen N I,Bell E F. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network[J].{H}PEDIATRICS,2010,(03):443-456.
  • 4Jobe A H. The new bronchopulmonary dysplasia[J].{H}Current Opinion in Pediatrics,2011,(02):167-172.
  • 5Stenmark K R,Abman S H. Lung vascular development:implications for the pathogenesis of bronchopulmonary dysplasia[J].{H}Annual Review of Physiology,2005.623-661.
  • 6Bhatt A J,Pryhuber G S,Huyck H. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor,Flt-1,and TIE-2 in human infants dying with bronchopulmonary dysplasia[J].{H}American Journal of Respiratory and Critical Care Medicine,2001,(10 Pt 1):1971-1980.
  • 7McGrath Morrow S A,Cho C,Cho C. Vascular endothelial growth factor receptor 2 blockade disrupts postnatal lung development[J].{H}American Journal of Respiratory Cell and Molecular Biology,2005,(05):420-427.
  • 8Mourani P M,Abman S H. Pulmonary vascular disease in bronchopulmonary dysplasia:pulmonary hypertension and beyond[J].{H}Current Opinion in Pediatrics,2013,(03):329-337.
  • 9Silvestri F,Banavali S,Baccarani M. The CD34 hemopoietic progenitor cell associated antigen:biology and clinical applications[J].{H}HAEMATOLOGICA,1992,(03):265-273.
  • 10Gordon M Y,Marley S B,Davidson R J. Contact-mediated inhibition of human haematopoietic progenitor cell proliferation may be conferred by stem cell antigen,CD34[J].{H}HEMATOLOGY JOURNAL,2000,(02):77-86.

引证文献5

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部